Effectiveness And Safety of Shorter Treatment Regimen Containing Bedaquiline in Patients with Multidrug-Resistant Tuberculosis

Oki N. Putra

Abstract


Bedaquiline have been included in the shorter treatment regimen (STR) to treat patients with multidrug-resistant tuberculosis (MDR-TB). The aim of this study is to evaluate the effectiveness and safety of STR containing bedaquiline. Data were collected retrospectively from medical records of MDR-TB patients receiving STR between January 2020 and December 2021. Sputum culture was evaluated at six months (24 weeks) and the end of treatment. Measurement of renal and liver function test, serum electrolytes, and uric acid were evaluated to assess safety during six months of treatment. Treatment failure, death, and loss to follow-up were also recorded during the study period. Thirty eligible MDR-TB met the inclusion criteria. Twenty-five of them had a positive culture at baseline. After treatment completion, 96.0% patients experienced sputum culture conversion. A significant decrease in potassium and calcium serum levels was observed at three months of treatment. Cases of treatment failure and loss to follow-up were 3.3% and 6.6%, respectively. MDR-TB patients receiving STR containing bedaquiline demonstrated favorable sputum conversion with tolerable safety profile

Full Text:

PDF

References


Panford V, Kumah E, Kokuro C, Adoma PO, Baidoo MA, Fusheini A, et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study. BMJ Open. 2022; 12:e062857. https://doi.org/ 10.1136/bmjopen-2022-062857

World Health Organization. Consolidated Guidelines on Tuberculosis Treatment. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva, Switzerland: World Health Organization;2020. https://www.who.int/publications/i/item/9789240007048. (Accessed 25.11.2022)

Sarathy JP, Gruber G, Dick T. Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline. Antibiotics. 2019;8:261. https://doi.org/ 10.3390/antibiotics8040261

Aslam H, Omar A, Fatima R, Rasool U, Yaqoob A, Ullah W, et al. Treatment outcomes and adverse drug reactions among patients with drug-resistant tuberculosis receiving all-oral, long-term regimens: first record viewing report from Pakistan. Asian Pacific Journal of Tropical Medicine. 2023;16(2):58-64

Wang MG, Wu SQ, He JQ. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):970. https://doi.org/10.1186/s12879-021-06666-8

Ministry of Health of Indonesia Republic. Techinal guide. Management of drug resistant tuberculosis in Indonesia. Indonesia. Ministry of Health of Indonesia Republic. 2020. https://tbindonesia.or.id/pustaka/pedoman/tb-ro/petunjuk-teknis-penatalaksanaan-tuberkulosis-resistan-obat-di-indonesia. (Accessed 28.11.2022)

Darmayani IG, Ascobat P, Institay I, Sugiri YJR, Sawitri N. Bedaquiline effect on QT interval of drugs-resistant tuberculosis patients: Real world data. ActaMed Indones. 2022;54(3):389-396

Primadana V, Yovi I, Estiningsih DS. Bedaquiline correlation to QT interval prolongation in DR-TB patients. Journal of Respirology. 2022;8(3):140–146. https://doi.org/10.20473/jr.v8-I.3.2022.140-146

Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar S v., Ismail NA, et al. Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: A prospective cohort study. Clin Infect Dis. 2021;73(11):2083–2092. https://doi.org/ 10.1093/cid/ciab335

Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597–602. https://doi.org/ 10.1016/j.cmi.2020.06.004

Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Indian J Tuberc. 2020;67(1):29–37. https://doi.org/10.1016/j.ijtb.2019.10.002

Kim CT, Kim TO, Shin HJ, Ko YC, Choe YH, Kim HR, et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: A multicentre cohort study in Korea. Eur Respir J. 2018;51(3):1702467. https://doi.org/ 10.1183/13993003.02467-2017

Phuong NTM, Minh LTH, Merle CSC, Pedrazzoli D, Linh NN, Decroo T, et al. Effectiveness and safety of bedaquiline-based, modified all-oral 9-11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam. Int J Infect Dis. 2023;126:148-154. https://doi.org/10.1016/j.ijid.2022.11.007

Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, Kiria N, et al. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020. Monaldi Arch Chest Dis. 2021;91(1):4-9. https://doi.org/10.4081/monaldi.2021.1679

Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, Santoso P, et al. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. PLoS One. 2022;17(1):e0263304. https://doi.org/10.1371/journal.pone.0263304

Fu L, Weng T, Sun F, Zhang P, Li H, Li Y, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;111:138–147. https://doi.org/10.1016/j.ijid.2021.08.055

Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, et al. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in mycobacterium tuberculosis infected C3HeB/FeJ Mice. ACS Infect Dis. 2016;2(4):251–67. https://doi.org/10.1021/acsinfecdis.5b00127

Sun F, Li Y, Chen Y, Guan W, Jiang X, Wang X, et al. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: A prospective cohort study. Eur Respir J. 2019;53(3):1801770. https://doi.org/10.1183/13993003.01770-2018

Kempker RR, Barth AB, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, et al. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2015;59(6):3149–3155. https://doi.org/10.1128/AAC.00379-15

Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, et al. Fluoroquinolones in drug-resistant tuberculosis: Culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection. Antimicrob Agents Chemother. 2019;63(7):e00279-19.https://doi.org/ 10.1128/AAC.00279-19

Sidamo T, Shibeshi W, Yimer G, Aklillu E, Engidawork E. explorative analysis of treatment outcomes of levofloxacin-and moxifloxacin-based regimens and outcome predictors in Ethiopian MDR-TB patients: A prospective observational cohort study. Infect Drug Resist. 2021;14:5473–5489. https://doi.org/10.2147/IDR.S342964

Anh LTN, Kumar AMV, Ramaswamy G, Htun T, Thi TTH, Nguyen GH, et al. High levels of treatment success and zero relapse in multidrug-resistant tuberculosis patients receiving a levofloxacin-based shorter treatment regimen in Vietnam. Trop Med Infect Dis. 2020;5(1):43. https://doi.org/10.3390/tropicalmed5010043

Shi L, Gao J, Gao M, Deng P, Chen S, He M, et al. Interim effectiveness and safety comparison of bedaquiline-containing regimens for treatment of diabetic versus non-diabetic MDR/XDR-TB patients in China: A multicenter retrospective cohort study. Infect Dis Ther. 2021;10(1):457–70. https://doi.org/10.1007/s40121-021-00396-9

Soedarsono S, Kusmiati T, Permatasari A. Effect of diabetes mellitus on renal and audiology toxicities in patients with drug-resistant pulmonary tuberculosis. Arch Clin Infect Dis. 2021;16(2);e99260. https://doi.org/10.5812/archcid.99260

Zheng H, He W, Jiao W, Xia H, Sun L, Wang S, et al. Molecular characterization of multidrug- resistant tuberculosis against levofloxacin, clofazimine, and delamanid in southwest of China. BMC Infect Dis. 2021;21(1):330. https://doi.org/10.1186/s12879-021-06024-8

Ghodousi A, Rizvi H, Baloch Q, Ghafoor A, Khanzada M. Cross acquisition of cross-resistance to bedaquiline and clofazimine following treatment for tuberculosis in Pakistan. Antimicrob Agents Chemother. 2019;63(9):e00915-19. https://doi.org/ 10.1128/AAC.00915-19

Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021;21(7):975–83. https://doi.org/10.1016/S1473-3099(20)30770-2

Nihlah NA, Almattin BN, Wicaksono IA. Adverse events of bedaquiline drug use in the treatment of multidrug-resistant tuberculosis (MDR-TB) patients: A Review. Pharmacology and Clinical Pharmacy Research. 2024;9(1):11-27

Ngwalero P, Brust JCM, van Beek SW, Wasserman S, Maartens G, Meintjes G, et al. Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis. Antimicrob Agents Chemother. 2021;65(11):e0239920. https://doi.org/10.1128/AAC.02399-20

Li J, Yang G, Cai Q, Wang Y, Xu Y, Zhang R, et al. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. Int J Infect Dis. 2021;110:179–186. https://doi.org/ 10.1016/j.ijid.2021.07.038

Tang JKK, Rabkin SW. Hypocalcemia-induced QT interval prolongation. Cardiology. 2022;147(2):191–195. https://doi.org/10.1159/000515985

Kusmiati T, Devina Suci Y, Purnama Dewi K. QTc interval prolongation in drug resistant-tuberculosis patients treated with shorter treatment regimen. Medico-legal Update. 2021;21(2):1208-1215. https://doi.org/10.37506/mlu.v21i2.2855

Azis FDA, Nurlaila H. Early detection of elevated liver function test in drug-resistant tuberculosis with short term therapy and individual therapy. Bali Medical Journal. 2022;11(1):324–327. https://doi.org/10.15562/bmj.v11i1.3113

Molla Y, Wubetu M, Dessie B. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med. 2021;13:1–8. https://doi.org/10.2147/HMER.S290542

Raj Mani S, Iyyadurai R, Mishra A, Manjunath K, Prasad J, Lakshmanan J, et al. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system. Int J Mycobacteriol. 2021;10(2):116–121. https://doi.org/ 10.4103/ijmy.ijmy_15_21

Louthrenoo W, Hongsongkiat S, Kasitanon N, Wangkaew S, Jatuworapruk K. Effect of antituberculous drugs on serum uric acid and urine uric acid excretion. J Clin Rheumatol. 2015;21(7):346–348. https://doi.org/ 10.1097/RHU.0000000000000297




DOI: https://doi.org/10.15416/pcpr.v9i3.57368

Refbacks

  • There are currently no refbacks.


                                                                         
Pharmacology and Clinical Pharmacy Research is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
                                                                      VIEW VISITOR STATS